2023
- 04
-
IND approval for TU7710 (bypassing agent for hemophilia)
Phase 1 clinical trial in Korea
- 03
-
TU2218 (immuno-oncology drug)
Phase 1b clinical trial in combination with Keytruda initiated
2022
- 11
-
TU2218 (immuno-oncology drug) selected for KDDF
(Korea Drug Development Fund) project
- 08
-
Out-licensing deal of TU2670 (endometriosis drug)
with Hansoh Pharma for the Chinese market
- 06
-
CTCSA (Clinical Trial Collaboration and Supply Agreement)
with MSD for Keytruda and TU2218 (Immuno-oncology drug)
- 02
-
CTCSA (Clinical Trial Collaboration and Supply Agreement)
with BeiGene for Tislelizumab and TU2218 (Immuno-oncology drug)